Introduction
We first formalize the quantal bioassay problem as follows. An experimenter wishes to investigate the potency of a stimulus by administering it at k dosage levels, t 1 , t 2 ,...,tk. A total of n i subjects are treated at level t i with the number of positive responses obtained denoted by Xi, i=1,2,...,k. The potency curve F is the distribution of tolerance levels, that is F(t) is the prohahility of achieving a positive response at dosage level t. We seek to make -about F. Parametric models as, for example, discussed in Finney (1978) typically specify F as a family of logit or probit forms. We take a nonparametric setting only assuming F to be an arbitrary right-continuous non-decreasing function whose range is [0,1].
Taking a Bayesian inferential framework, we note that the fully Bayesian nonparametric approach to estimating the tolerance distribution in a quantal bioassay has not previously been implemented due to computational difficulties. Antoniak (1974) has shown that, under Ferguson's Dirichlet process prior (1973) , the posterior distribution of the potency curve is a mixture of Dirichlet process distributions. Unfortunately this mixture becomes increasingly intractable as the number of observed dosage levels increases. In her unpublished dissertation, of M.N. Wesley abandons calculation of the posterior expectation of the potency curve at the observed dosage levels because of such difficulties, estimating, * instead, the posterior mode. Kuo (1988) , again in deference to these difficulties, obtains linear Bayes estimates under squared error loss. Related previous Bayesian work includes Kraft and Van Eeden (1964) , Ramsey (1972) , Bhattacharya (1981) , Disch (1981) and Ammann (1984) .
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This paper has two objectives. First, we show how fully Bayesian analysis to obtain for any t, the posterior distribution of F(t) given the data X = (X 1 , X 2 ,. ..,Xk) can be straightforwardly implemented under two rich classes of prior specification. In addition, features of these distributions such as mode, expectations and quantiles can be readily obtained. Second, we provide a useful extension of the quantal bioassay model which allows ordered polytomous response arising from stochastically ordered potency curves. Missing data can be readily handled. To our knowledgi, no literature on Bayesian approaches to this problem exists.
The format is the following. In Section 2 we develop the details to implement the first objective. Section 3 provides an illustrative example using the Dirichlet process prior with a data set from Cox and Snell (1989) . In Section 4 we develop the aforementioned extension while in Section 5 we provide an illustrative example adapted from Maxwell (1961) for the case of two ordered response levels utilizing a product-Beta class of priors. Section 6 offers brief summary and discussion.
Models, Distribution Theory and Inference For the Basic Bioassay Problem
We assume the responses, Xi, to the dosage levels t, are independently distributed as Binomial Bi(ni,pi) with pi = F(ti) where F(t) is an unknown underlying potency curve yielding the probability of a response at dosage level t.
H1c.ce the likelihood at X = x is
where P = (Pl,...,pk).
Interest focuses on inference regarding the pi's and the function F.
Often F is given a parametric form F(t;0) such as a scale and location logistic or probit curve. This literature is large. See, for example, Finney (1978) for discussion and references. Here we assume F belongs to the nonparametric class of right-continuous non-decreasing functions taking values in [0,1].
The Bayesian framework requires specification of a prior which represents our beliefs regarding F(t). Practically this necessitates fhl-C-ecification of a joint measure for p with density denoted by h(p) wawch 6y assumptions on F is over the set Sk = {p: 0_Pl ... pk11. One family of priors which has been discussed in this context in the literature is the Dirichlet process prior introduced by Ferguson (1973) . Kuo (1988) provides a recent summary of this discussion.
This specification assumes that F is close to some given F o with closeness quantified by a given precision M. More precisely, for any t, the induced prior on F(t) is a Beta distribution, Be[MFo(t), M{1-Fo(t)}]. Since E{F(t)} = Fo(t) and Var{F(t)} = Fo(t){1-Fo(t)}/(M+i), F o and M have interpretations which facilitate their specification from prior information. in particular F° is usually taken to be a standard distribution whose median agrees with our prior guess for the LD50 and whose spread provides rough agreement with our prior expectations at other dosage levels. M is chosen to reflect our confidence in F in accord with the extent of our prior experience. In practice 
where -ti= M{Fo(ti) -Fo(ti-l)}' i=l,...,k+l. Here we assume to = --, Fo(to) = 0, tk+1 = , Fo(tk+l) = 1, so that Dyi = M. Marginal and conditional distributions and expectations under (2) are routine.
A second class of priors for p is the product-Beta. This family has been cuscussed in unpublished work of L. Sharples and takes the form
where a = (al,...,ak), /3 -( 0 I,..Xk) and ck is the normalizing constant under restriction to S k . Sharples shows that ck can be expressed as a finite multidimensional summation.
Note that 7 rB offers mathematical convenience in that it is conjugate with respect to (1) while irD is not. The family (3) is a flexible class of priors but it is not clear how to select a and # in accord with prior information.
That is, unlike 7 rD' IB is not induced in any obvious way from a prior on F since it is specified within dosage levels rather than across them. However IB can be chosen to reflect to prior information about F in terms of a given F°a nd given precision. Letting e(i) denote a row vector having value 1 at the ith coordinate, 0's elsewhere, expectations involving the pi may be formally given, e.g., EB(Pi) = Ck(a, /)/ck(a + e ( i), 0 ). This suggests equating EB(Pi) = Fo(ti), i = 1,...,k. Moreover, M i -a i + 0i can be viewed as a precision 6 parameter analogous to M above. The magnitude of M i reflects our confidence in the value F 0 (ti). With specification of M i we obtain k equations in k unknowns. Unfortunately, explicit calculation of the EB(Pi) will be infeasible except in very special cases making solution of this system of equations virtually impossible. However, the conditional distribution of pi given pj, j~i is obviously a Beta distribution, Be(ai, Oi) restricted to [pil, Pi+1]" Though, again, the mean of this conditional distribution will not be available explicitly the mode is readily obtn,-o It is pi -(ai-1)/(Mi-2) provided ai>1, 0i>l
and Pi-1 -pi -p + " JLaiung pi as an approximation to the marginal mode for pi we equate it to Fo(ti) whence ai = (Mi-2) Fo(ti) + 1 and Oi = M -a. We note that in our illustrations sampling is conducted with v 7 independent parallel replications each taken to r iterations. Choice of v determines how close our density estimate is to the exact density at the rth iteration the order of convergence being 0(v-l ). Choice of r determines how close the latter density is to the actual marginal posterior density with convergence at an exponential rate (Geman and Geman, 1984; Tanner and Wong, 1987) . Settings for r and v to achieve smooth converged estimates vary with the application and require diagnostic assessment as in .
Objects of primary interest for
For the examples in sections 3 and 5 r = 20 and v = 1000.
Each of the priors (2) and ( Zi(2) = (Zi,i+,...,Zi.k+1) , Zi(l) and Zi(2) are conditionally independent given
After v independent replications each to the rth iteration we obtain (p(r), z(r)'""z(r) ' s=l,...,v. The resulting estimate for the marginal posterior density of pi is }D(Pi I X) = v-I~ F " gD(Pi I X' Z I '"zrks I js i 4
Similarly the posterior mean of pi is estimated using the mean of gD leading to -1 v ,,,r) + ((r) (r) -
where + i j=1,t..+k+1.
A posterior density estimate for F(t) at say t=t may be obtained by Expression (6) shows that once the posterior means for the pi's have been computed using (5), an elementary interpolation formula enables ED(F(t) I X) for any t. This formula was first noted by Antoniak (1974) . The unpublished Ph.D. theses of M.N. Wesley also discusses (6) as well as computation of ED(Pi IX). In fact, she obtains exact formulas for these e.,ctations for up to four dosage levels but evaluation of these formulas even for three levels is a forbidding task. By comparison, the estimate (5) is routine to evaluate regardless of the number of dosage levels. Moreover, using the above estimates of the posterior densities for the p 1 and F(t) we may straightforwardly obtain other features of these densities such as modes and quantiles.
For KB, examination of (1) and (3) reveals that the complete conditional distribution of P 1 IX, pj, j#i, is that of a Beta(a + X i , Oi + ni -Xi) restricted to [P-l Pi+1 ] which we denote by gB(Pi Xi, Pi' " Sampling from by retaining appropriately restricted draws from the unrestricted Beta 10 distribution will be very inefficient when pi+l -Pi-1 is small. One-for-one sampling from gB may be achieved through the use of the incomplete Beta .unction which is incorporated into many scientific subroutine libraries. If G(y)
P{Y~yIY-Beta(a,b)} then Z is distributed as Beta(a,b) restricted to [c,d] if 
Use of (7) is preferred to a kernel density estimate based upon the p) since, by using the conditional structure of the model, substantially smaller v is needed (see . Though standardization is required to obtain each gB in (7) this requires only a univariate rumerical integration and can be done quite rapidly using simple trapezoidal or Simpson's rule integration. Since moments of gB are not available explicitly, an expression such as (5) is unavailable for EB(Pi I X); posterior moments of pi are most easily calculated using the p (r) pis
A posterior density estimate for F(t) at say t=t may be obtained by including F(t*) as an additional model parameter. More precisely, as with D'
we revise the prior to include F(t) and to take the form lrB(p) • hB(F(t)Ip).
*
Paralleling the development below (3) if t 4~ti, ti+l], hB is naturally a Beta(a , ) restricted to [Pi' pi+l ) where with M a + 0 specified, a =(M -2)Fo(t ) + 1 and 0 =M -a. Again, in the abonce of data at dosage level t ,the complete conditional distribution for F(t) is hB(F(t )p) 11 so that the posterior density estimate for F(t*) becomes v-1 E hB(F(t) Ipr)).
Again one dimensional numerical integration to standardize hB is required. Unfortunately no interpolation formula analogous to (6) is available for EB(F(t) IX).
A Numerical Example
The data for this example are taken from an illustrative Table 1 also shows the nonparametric Bayes estimates, (5), of F(ti) for each value of M using the Gibbs sampler with a total of r = 20 iterations and v = 1000
replications. The supplied standard deviation (S.D.) measures the variation amongst these replications and also is an estimate of the marginal posterior standard deviation of F(ti). Interval estimates for the F(ti) were obtained using the empirical distribution of the 1000 estimates from the 1000 replications.
In particular, equal tail 95 percent confidence intervals are given here.
Under 7 rD the Bayes estimate of F(t) can be obtained using the interpolation formula (6). 
Ordered Potency Curves
We extend the model of Section 2 to allow ordered polytomous response arising from stochastically ordered potency curves. Suppose for a given stimulus we observe whether or not each of two events occurred-such that one is contained within t,, o ,. For example, event A might be "patient died" while event C
might be "patient's condition worsened" whence A C C. Other illustrations include: in response to a dosage of medication, A is "improvement in a particular metabolic index", C is "improvement or no change in this index"; in response to hours of tutoring, A is a "high pass" on a standardized exam, C is a "pass" on this exam. We show here how the approach of Section 2 can be extended to handle such situations with further extension to more than two nested events being obvious. The case of non-nested events as for example if A is a decline in blood pressure while C is a decline in cholesterol level is not handled here. Formalizing notation, suppose at level ti, i=1,2,...,k we observe n.
subjects with event A occurring X i times, event C occurring Yi times with A c C so that X i < Yi. We model this situation with two underlying potency curves FA(t), FC(t) which are stochastically ordered, i.e., FA(t) < FC(t).
Letting pi -F A(ti) < qi --FC(ti) we assume that the joint distribution of X.
and Yi is specified through (Xi, Yi-Xi) -Mult (ni; pi, qi-Pi, 1"qi). Hence with p = (pl,...,pk) and q = (ql,-..,qk) the likelihood at X = x, Y -y is k n.
xy 1 -x. n.-y.
Interest focuses on inference regarding the pi 's and qi's as well as FA and F C. Prior specification is restricted to the set Tk =(p,q)
: 0 <1 p,. Pk 0 <-2 .. qk S ,pi for all i). We consider two families of priors extending rD and 7rB respectively.
In extending 7 rD the Dirichiet process prior is replaced by a product Dirichlet process prior with stochastic :'-rd'cr. We do not attempt formal definition or investigation of such measures here. Rather, if F A is close to some given F Ao with precision MA and F C is close to some given F 0 oWith precision M C then for any t we assume that the joint prior on (F A(t), FC (t)) is of the form (1-qj) J
where again c is the standardizing constant. Linking 7rB(p,q) to prior information can be done similar to that for rB(p) using the condition'.1 modes of pi and of qi-Pi. Assuming a i + Oi + 6. = Mi Mi specified, with ai, i, I
Implementation of our sampling approach for the prior (10) is simplified by the introduction of unobserved multinomial variables as in Section 2.
Associating ZA with event A, Z C with event C, i=1, ...,k the distribution I 1 theory proceeds similarly to that in Section 2 leading to marginal posterior density estimates for pi and qi analogous to (4). Unfortunately the restriction pi -qi precludes explicit calculation of complete conditional moments so that there is no analogue to (5); we use the p(r) s=1,...,v, to obtain posterior expectations. Posterior density estimates for FA(t ) and Fc(t) along with interpolation formulas for posterior expectations can be developed paralleling the discussion below (5) leading to (6). For the prior (11) distribution theory and sampling parallel that above (7). Posterior density estimates analogous to (7) arise along with posterior density estimates for FA(t ) and for Fc(t). The use of (11) is illustrated with an example in Section 5.
It is worth noting that, regardless of prior, missing data can be readily handled. For instance, should X i be unavailable we need only include it as an additional parameter in the model. Complete conditional distributions for each of the other parameters when X i is given as well will be exactly as before while the complete conditional distribution of X i will be Bi(Y, pi/qi).
A Second Numerical Example
The data in Table 2 is taken from Maxwell (1961, p. 70). In his table eacn oi k23 boys is classified into one of five different age groups and is assigned a rating on a four point scale (-1, 0, 1, 2) for the symptom of "disturbed dreams".
A rating of 2 denotes the most severe suffering from bad dreams while a rating of -1 denotes no suffering at all. To simplify the illustration we combine the two intermediate categories, ratings 0 and 1, into one to obtain Table 2.
In the context of Section 4 we envision two underlying "potency" curves.
One is associated with the event A, "rank -1 is assigned", that is, no suffering from bad dreams. The other is associated with the event C, "rank -1, 0 or 1 is assigned", that is, no suffering or mild suffering from bad dreams. With these definitions, curves for the incidence of A and of C which are monotonically increasing with age seem reasonable. Obviously A C C thus ordering the curves.
Labeling the five age categories from youngest to oldest as 0, 1, 2, 3, and 4, for category i, X i counts the incidence of A, Yi counts the incidence of C. The top part of Table 3 converts Table 2 to this notation.
The product Beta prior, (11), is taken here. For illustration we assume here that all prior precisions M i are equal to 10, that FA,o is N(2,4) and that FC, o is N(1,4). For each age category prior incidence probabilities associated with these two curves appear in Table 3 along with ai, #i and 6. 
Summary and Discussion
Nonparametric bioassay is inherently attractive in freeing us from parametric specification of a form for the presumed underlying potency curve.
Similarly, Bayesian inference is attractive for the bioassay problem since we often have prior knowledge regarding the potency curve, e.g., the LD50, the steepness, etc. While Bayesian nonparametric problems are typically quite hard, the fact that the bioassay setting provides a binomial likelihood enables simplification particularly with regard to prior specification. Even so, previous attacks have enjoyed limited success in developing desired marginal posterior distributions and their features due to computational difficulties. However, the Gibbs sampler approach is shown to be well-suited for the general handling of such "likelihood x prior" forms. Moreover, a potentially useful extension can be handled as well through this sampling-based approach. Other extensions, for instance, to multivariate dichotomous response and to nominal polytomous response are worthy of further investigation.
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